PAVmed Inc

PAVM · NASDAQ · Healthcare / Medical Devices

1.63USD+0.29 (+21.73%)

Price History

Full chart

Market Stats

Previous Close1.34

Open1.47

Day Range1.43 – 1.69

52-Week Range3.70 – 17.99

Volume56.44K

Market Cap37.85M

P/E (TTM)0.00

Forward P/E0.00

EPS-17.03

Dividend Yield0.00%

Beta0.54

50-Day Avg4.86

200-Day Avg7.35

About

PAVmed Inc. engages in acquiring, developing, and commercializing novel products that target unmet needs in the United States. The company's lead products include CarpX, a patented, single-use, disposable, and minimally invasive surgical device for use in the treatment of carpal tunnel syndrome; EsoCheck Esophageal Cell Collection Device, which consists of diagnostic test that serves as a testing tool for preventing esophageal adenocarcinoma deaths, through early detection of esophageal precancer in at-risk gastroesophageal reflux disease, including chronic heartburn and acid reflux or simply reflux in patients; and EsoGuard, a bisulfite-converted next-generation sequencing DNA assay performed on surface esophageal cells collected with EsoCheck device. Its product pipeline also comprises EsoCure Esophageal Ablation Device for treating dysplastic BE; PortIO, an implantable intraosseous vascular access device; and Veris cancer care platform. The company was formerly known as PAXmed Inc. and changed its name to PAVmed Inc. in April 2015. PAVmed Inc. was incorporated in 2014 and is headquartered in New York, New York.

Company Details

SectorHealthcare
IndustryMedical Devices
CEODr. Lishan Aklog M.D.
Employees41
Headquarters360 Madison Avenue, New York, NY, United States, 10017, USA
Websitehttps://www.pavmed.com

Leadership

Dr. Lishan Aklog M.D.Chairman & CEO · b. 1966
Mr. Dennis M. McGrath C.P.A.President & CFO · b. 1957
Mr. Shaun M. O'Neill M.B.A.Executive VP & COO · b. 1982
Mr. Michael Adam GordonExecutive VP, General Counsel & Secretary · b. 1975
Dr. Brian J. deGuzman M.D.Executive VP, Chief Technology & Compliance Officer · b. 1965
Dr. Suman M. Verma M.D., Ph.D.Senior VP of Molecular Genetics & Chief Scientific Officer
Mr. Matthew RileySenior Director of Investor Relations
Dr. Deepika A. Lakhani Ph.D.Senior VP, Chief Regulatory & Quality Officer
Dr. Victoria T. Lee M.D.Executive Vice President & Chief Medical Officer · b. 1986
Mr. Joseph VirgilioSVP & Chief Business Officer of Medical Devices · b. 1975

Financials

Income Statement

Currency: USD	2014-12-31	2015-12-31	2016-12-31	2017-12-31	2018-12-31	2019-12-31	2020-12-31	2021-12-31	2022-12-31	2023-12-31	2024-12-31	2025-12-31
Total Revenue	0	0	0	0	0	0	0	500.00K	377.00K	2.45M	3.00M	71.00K
Growth (%)	-	-	-	-	-	-	-	-	-24.60%	+550.40%	+22.15%	-97.63%
Cost of Revenue	0	0	3.79K	7.11K	9.79K	14.23K	23.00K	585.00K	3.61M	6.42M	6.04M	323.00K
Gross Profit	0	0	-3.79K	-7.11K	-9.79K	-14.23K	-23.00K	-85.00K	-3.24M	-3.97M	-3.04M	-252.00K
Gross Margin	-	-	-	-	-	-	-	-17.00%	-858.62%	-161.83%	-101.60%	-354.93%
Operating Expense	422.29K	1.78M	5.65M	8.03M	10.55M	14.28M	23.33M	54.31M	87.85M	64.83M	41.44M	21.55M
Operating Income	-422.29K	-1.78M	-5.65M	-8.03M	-10.56M	-14.30M	-23.35M	-54.39M	-91.09M	-68.80M	-44.49M	-21.81M
Operating Margin	-	-	-	-	-	-	-	-10878.60%	-24161.01%	-2805.67%	-1485.38%	-30712.68%
EBITDA	-126.48K	-1.78M	-5.65M	-11.15M	-12.07M	-16.67M	-23.33M	-55.90M	-99.50M	-75.74M	29.67M	-2.34M
EBITDA Margin	-	-	-	-	-	-	-	-11180.00%	-26392.57%	-3088.99%	990.65%	-3300.00%
Net Income	-548.77K	-1.78M	-5.65M	-9.52M	-17.97M	-15.93M	-34.28M	-50.35M	-88.98M	-64.17M	39.79M	401.00K
Net Income Margin	-	-	-	-	-	-	-	-10069.40%	-23602.92%	-2617.25%	1328.58%	564.79%
R&D	22.29K	489.33K	1.72M	2.62M	4.25M	6.63M	10.96M	19.85M	25.34M	14.28M	5.93M	4.49B
R&D as % of Total Revenue	-	-	-	-	-	-	-	3969.40%	6720.95%	582.22%	198.06%	6326760.56%
Interest Expense	0	0	0	724.68K	2.39M	32.67K	53.00K	5.78M	1.28M	589.00K	45.00K	21.00K
Interest Expense % of Total Revenue	-	-	-	-	-	-	-	1155.80%	339.79%	24.02%	1.50%	29.58%

Balance Sheet

Currency: USD	2014-12-31	2015-12-31	2016-12-31	2017-12-31	2018-12-31	2019-12-31	2020-12-31	2021-12-31	2022-12-31	2023-12-31	2024-12-31	2025-12-31
Total Assets	842.08K	1.21M	870.42K	1.64M	8.50M	7.24M	19.78M	86.98M	53.98M	33.12M	30.66M	38.81M
Total Liabilities	47.25K	580.17K	1.19M	4.49M	10.97M	11.88M	20.25M	7.56M	43.05M	57.14M	37.69M	16.51M
Total Equity	794.83K	633.92K	-319.07K	-2.85M	-2.31M	-3.82M	1.90M	61.67M	-9.68M	-53.83M	-2.50M	33.97M
Cash	839.08K	767.27K	585.68K	1.54M	8.22M	6.22M	17.26M	77.26M	39.74M	19.64M	1.19M	1.54M
Total Debt	-	-	-	3.89M	7.90M	8.14M	14.96M	-	36.64M	48.73M	31.86M	13.35M
Net Debt	-839.08K	-767.27K	-585.68K	409.25K	-319.12K	1.92M	-2.30M	-77.26M	-3.11M	29.09M	30.68M	11.81M

Cash Flow

Currency: USD	2014-12-31	2015-12-31	2016-12-31	2017-12-31	2018-12-31	2019-12-31	2020-12-31	2021-12-31	2022-12-31	2023-12-31	2024-12-31	2025-12-31
Operating Cash Flow	-60.27K	-1.25M	-4.45M	-6.61M	-8.79M	-13.36M	-21.91M	-40.59M	-70.98M	-52.04M	-33.55M	-5.21B
Investing Cash Flow	-21.79K	-21.79K	-21.79K	-5.30K	-26.61K	-27.20K	-55.00K	-3.72M	-4.74M	758.00K	-16.18M	-31.00M
Financing Cash Flow	1.74M	1.18M	4.30M	7.56M	15.50M	11.38M	33.01M	104.31M	38.21M	31.17M	31.28M	5.59B
Capital Expenditure	21.79K	21.79K	21.79K	5.30K	26.61K	27.20K	55.00K	1.47M	1.54M	242.00K	55.00K	31.00K
Free Cash Flow	-60.27K	-1.25M	-4.48M	-6.61M	-8.81M	-13.38M	-21.97M	-42.06M	-72.53M	-52.28M	-33.61M	-5.21B
Dividends Paid	-	7.10K	7.10K	7.10K	7.10K	67.44B	357.00K	436.00M	35.23M	12.55B	-	-
FCF to OCF	100.00%	100.00%	100.49%	100.08%	100.30%	100.20%	100.25%	103.62%	102.17%	100.47%	100.16%	100.00%
Dividend Paid to FCF	-	-0.57%	-0.16%	-0.11%	-0.08%	-503837.51%	-1.63%	-1036.61%	-48.57%	-24002.45%	-	-

Earnings

Report Date	Aug 12, 2016	Nov 10, 2016	Feb 16, 2017	May 22, 2017	Aug 11, 2017	Nov 14, 2017	May 21, 2018	Aug 13, 2018	Nov 14, 2018	Mar 31, 2019	May 15, 2019	Aug 14, 2019	Nov 19, 2019	Dec 31, 2019	May 21, 2020	Aug 14, 2020	Nov 6, 2020	Feb 22, 2021	May 17, 2021	Aug 12, 2021	Nov 16, 2021	Mar 29, 2022	May 12, 2022	Aug 15, 2022	Nov 14, 2022	Mar 13, 2023	May 15, 2023	Aug 14, 2023	Nov 13, 2023	Mar 25, 2024	May 13, 2024	Aug 12, 2024	Nov 14, 2024	Mar 24, 2025	May 15, 2025	Aug 14, 2025	Nov 12, 2025	Mar 30, 2026	May 14, 2026	Aug 14, 2026	Nov 12, 2026
EPS Estimate	-0.09	-67.50	-63.00	-63.00	-63.00	-63.00	0.02	-49.50	-54.00	-0.14	-58.50	-58.50	-45.00	-0.11	-49.50	-49.50	-49.50	-0.11	-40.50	-40.50	-42.75	-0.15	-85.50	-90.00	-105.75	-0.25	-74.25	-69.75	-63.00	-53.70	-1.67	-40.20	-39.00	-0.40	-0.31	-7.50	-6.00	-4.50	-0.69	-0.66	-0.66
EPS Actual	-0.10	-63.00	-58.50	-63.00	-36.00	-86.76	0.02	-54.86	-37.44	-0.15	-58.50	-58.50	-45.00	-0.19	-148.50	-58.50	-45.00	-0.17	-36.00	-36.00	-45.00	-0.20	-63.00	-76.50	-67.50	-0.23	-54.86	-46.41	-37.45	-46.92	-2.62	-6.00	-16.20	-0.19	-0.14	-1.50	-0.60	-1.05	-1.17	-0.42	-
Surprise	-11.11%	6.67%	7.14%	0.00%	42.86%	-37.71%	0.00%	-10.83%	30.67%	-7.14%	0.00%	0.00%	0.00%	-72.73%	-200.00%	-18.18%	9.09%	-54.55%	11.11%	11.11%	-5.26%	-33.33%	26.32%	15.00%	36.17%	8.00%	26.11%	33.46%	40.56%	12.63%	-56.89%	85.07%	58.46%	52.50%	54.84%	80.00%	90.00%	76.67%	-69.57%	36.36%	-
Timing	After-hours	After-hours	After-hours	After-hours	After-hours	After-hours	After-hours	After-hours	After-hours	After-hours	After-hours	After-hours	After-hours	-	After-hours	After-hours	After-hours	Pre-market	After-hours	After-hours	After-hours	After-hours	After-hours	After-hours	After-hours	After-hours	After-hours	After-hours	After-hours	After-hours	After-hours	Pre-market	Pre-market	After-hours	Pre-market	Pre-market	After-hours	-	After-hours	Pre-market	Pre-market

Key Statistics & Ratios

Market Cap37.85M

Enterprise Value49.52M

Trailing P/E0.00

Forward P/E0.00

PEG Ratio0.00

Price / Sales337.90

Price / Book1.04

EPS-17.03

Book Value4.98

Revenue (TTM)112.00K

Gross Profit (TTM)-247.00K

EBITDA-26.62M

Profit Margin0.00%

Operating Margin-21278.79%

Return on Equity-64.78%

Return on Assets-39.69%

Shares Outstanding9.84M

Shares Float4.10M

Beta0.54

Dividend Yield0.00%

Dividend Rate0.00

Payout Ratio0.00%

Analyst Ratings

Strong Buy

Based on 2 analystsTarget 36.50

Strong Buy
1
Buy
1

Ownership Breakdown

Institutions: 26.26%
Insiders: 41.44%
Retail / Other: 32.30%

Top Institutional Holders

Two Seas Capital LP
461.54K49.74%
First Manhattan Co. LLC
23.80K2.57%
Geode Capital Management, LLC
11.78K1.27%
Vanguard Capital Management, LLC
5.92K0.64%
Vanguard Fiduciary Trust Co
5.43K0.59%
BlackRock Inc
2.42K0.26%
Tower Research Capital LLC
6220.07%
Morgan Stanley - Brokerage Accounts
1650.02%
CWM, LLC duplicate
1570.02%
UBS Group AG
750.01%
SBI Securities Co Ltd
670.01%
Vanguard Global Advisers, LLC
610.01%
Wells Fargo & Co
450.00%

Top Fund Holders

Fidelity Extended Market Index
32.02K0.40%
iShares Micro-Cap ETF
16.66K0.21%
Fidelity Nasdaq Composite Index
3.01K0.04%
Fidelity Series Total Market Index
1.22K0.02%
1290 VT Micro Cap K
8810.01%
Fidelity Total Market Index
2620.00%
JHVIT Total Stock Market Index I
2260.00%

Stock Splits

Jan 2, 20261:30
Dec 7, 20231:15